Fentanyl

• Drug Class: Synthetic opioid analgesic; potent μ-opioid receptor agonist
• Core Uses: Potent synthetic μ-opioid agonist (about 50–100 times more potent than morphine by weight) used IV/IN for rapid-onset analgesia, adjunct to induction/intubation, and ICU/OR analgesia-sedation; transdermal and transmucosal forms are for chronic pain, not acute titration
• Hemodynamic Profile: Relatively hemodynamically stable compared with many other opioids when given slowly, but can still cause hypotension (especially with hypovolemia or sedative co-admins) and almost always causes some respiratory depression dose-dependently
• IV Adult Analgesic Bolus: 25–100 mcg IV every 5–10 minutes titrated to effect (roughly 0.35–1.5 mcg/kg for an average adult). For more controlled titration, 0.5–1 mcg/kg IV over 2–5 minutes is common, with smaller redoses
• RSI/Induction Adjunct: 1–3 mcg/kg IV (ideal body weight) administered over 30–60 seconds before laryngoscopy to blunt sympathetic response and provide analgesia, particularly in patients with suspected elevated ICP, acute coronary syndromes, or aortic dissection
• ICU/OR Continuous Infusion: Often 0.5–10 mcg/kg/hour IV (0.01–0.17 mcg/kg/min), titrated to pain/sedation scores; some protocols use even higher transient rates in the OR. Context-sensitive half-time increases with infusion duration, so accumulation occurs with prolonged use
• Intranasal (IN) Fentanyl: Commonly 1–2 mcg/kg (max 100–200 mcg) for acute severe pain, using 50 mcg/mL IV solution via mucosal atomization device; doses are often divided between nares. Useful in prehospital and pediatric settings when IV access is delayed
• Onset: IV onset within 1–2 minutes with peak effect at ~3–5 minutes; duration after a small bolus is usually 30–60 minutes. IN onset is typically within 5–10 minutes with peak around 10–20 minutes
• Major Acute Risks: Respiratory depression and apnea, chest wall and glottic rigidity (especially with high, fast IV doses), bradycardia, hypotension, nausea/vomiting, and rarely laryngospasm. Naloxone reverses respiratory depression but may also precipitate acute withdrawal or severe pain
• Critical Warning: Transdermal and transmucosal fentanyl products are reserved for opioid-tolerant chronic pain patients because of high potency, delayed offset, and overdose risk; they should NOT be initiated for acute pain in opioid-naïve patients in the ED/ICU

• Generic Name: Fentanyl citrate (most parenteral formulations)
• Brand Names: Sublimaze (IV), Duragesic (transdermal), Actiq/Fentora/Onsolis (transmucosal), multiple generics—availability is region- and institution-specific

Synthetic opioid analgesic; potent μ-opioid receptor agonist

Mechanism of Action:

• Fentanyl is a highly potent μ-opioid receptor agonist that binds to μ receptors in the CNS and peripheral tissues, inhibiting adenylate cyclase, decreasing cAMP, and modulating ion channels (increased K⁺ efflux and decreased Ca²⁺ influx)
• This leads to hyperpolarization of neurons and reduced neurotransmitter release (e.g., substance P, glutamate) in pain pathways, resulting in profound analgesia and blunting of the affective response to pain
• At the brainstem and pontine respiratory centers, fentanyl reduces responsiveness to CO₂ and hypoxia, producing dose-dependent respiratory depression and decreased respiratory rate/tidal volume
• In the cardiovascular system, fentanyl has relatively minimal direct myocardial depressant effects compared with some sedatives, but vagotonic effects and histamine-independent vasodilation can contribute to bradycardia and hypotension, especially when combined with other agents or in hypovolemia
• High-dose, rapid IV administration is associated with rigid chest-wall and glottic muscle tone ("wooden chest"), likely mediated by μ receptors in brainstem loci and spinal cord; this can severely impair ventilation and mask as refractory bronchospasm without muscle relaxant

Pharmacokinetics (IV and Intranasal):

• Formulations: IV injection solution typically 50 mcg/mL (in 2 mL or 10 mL vials), higher-concentration vials or premixed infusions in some institutions; transdermal patches (12–100 mcg/hour) and various transmucosal products for chronic pain
• Onset (IV): Analgesic effect begins within 1–2 minutes after IV bolus, with peak effect ~3–5 minutes. Duration of a small bolus is typically 30–60 minutes, depending on dose and patient factors
• Onset (IN): Analgesic effect generally begins within 5–10 minutes, with peak effect around 10–20 minutes; bioavailability via IN route is approximately 70–90% depending on formulation and technique
• Distribution: Highly lipophilic with rapid distribution to CNS and other highly perfused tissues; large volume of distribution (~3–8 L/kg). Rapid redistribution from brain to peripheral tissues explains the short duration of a single bolus
• Protein Binding: ~80–85% bound to plasma proteins (mostly α1-acid glycoprotein)
• Metabolism: Primarily hepatic metabolism via CYP3A4 to inactive metabolites (e.g., norfentanyl); minimal active metabolites compared with some other opioids
• Elimination: Metabolites are primarily excreted in urine; terminal elimination half-life is typically 3–8 hours, but the context-sensitive half-time increases substantially with prolonged infusions (hours to >10 hours in long infusions)
• Renal Impairment: Clearance of fentanyl itself is relatively preserved, but accumulation of metabolites and altered protein binding can occur; dose reductions and slower titration are recommended in severe renal dysfunction
• Hepatic Impairment: Reduced metabolism can increase fentanyl exposure and prolong effect; use lower initial doses and slower titration with close monitoring

• Acute moderate-to-severe pain in the ED, prehospital, or inpatient setting when IV/IN opioids are indicated (trauma, post-op, abdominal pain, ACS, etc.)
• Adjunct to induction and rapid sequence intubation to provide analgesia and blunt sympathetic responses to laryngoscopy (tachycardia, hypertension, increased ICP)
• Analgesia-sedation in mechanically ventilated ICU patients (often as a continuous infusion with or without other sedatives)
• Perioperative analgesia in the OR as part of balanced anesthesia
• Intranasal fentanyl for rapid analgesia when IV access is delayed or challenging, especially in pediatric or prehospital populations
• Transdermal and transmucosal formulations for chronic cancer or chronic non-cancer pain in opioid-tolerant patients (specialist-directed)
• Traumatic injuries (fractures, burns, soft tissue injury) requiring rapid IV/IN analgesia
• Acute coronary syndromes and other severe chest pain syndromes (used with caution due to potential masking of ischemic pain and hemodynamic effects)
• Postoperative pain control (IV bolus or infusion, transitioning to other regimens)
• Severe abdominal pain (e.g., pancreatitis, bowel obstruction, renal colic) requiring titratable opioid analgesia

Available Forms:

• IV Injection: Typically 50 mcg/mL in 2 mL (100 mcg) or 10 mL (500 mcg) vials/ampoules. Some facilities stock premixed infusions (e.g., 1000–2500 mcg in 50–100 mL NS/D5W)
• Intranasal Use (Off-Label in Many Regions): IV 50 mcg/mL solution delivered via mucosal atomization device; doses often split between nares
• Transdermal Patches: 12, 25, 50, 75, 100 mcg/hour (intended for opioid-tolerant chronic pain patients; NOT for acute titration)
• Transmucosal Products: Oral lozenges, buccal tablets/films, and nasal sprays for breakthrough cancer pain in opioid-tolerant individuals

Standard Dosing – Fentanyl (IV and Intranasal – Always Follow Local Protocols and Opioid/Sedation Guidelines):

Contraindications (Acute IV/IN Use):

• Known hypersensitivity to fentanyl or other phenylpiperidine opioids (e.g., sufentanil, alfentanil, remifentanil)
• Severe, uncorrected respiratory depression or acute severe asthma in non-ventilated patients (relative; may still be used with airway support)
• Caution/avoidance in patients with acute or severe bronchospasm where chest wall rigidity may worsen ventilation if muscle relaxants and airway control are not immediately available

Major Precautions:

• Elderly, frail, or opioid-naïve patients: Increased sensitivity to respiratory depression and hypotension; use reduced doses and slower titration
• Severe COPD, OSA, neuromuscular disease, or intracranial pathology: Monitor closely for hypoventilation and CO₂ retention; consider lower doses and alternative agents as appropriate
• Concurrent CNS depressants (benzodiazepines, propofol, alcohol, gabapentinoids): Additive respiratory and hemodynamic depression; adjust doses accordingly and intensify monitoring
• Bradyarrhythmias or conduction disease: Fentanyl can cause vagally mediated bradycardia; consider anticholinergic premedication in high-risk OR cases
• Hepatic impairment: Reduced clearance and prolonged effect; start with lower doses and titrate cautiously
• Transdermal/transmucosal fentanyl: Use only in opioid-tolerant patients meeting labeled criteria; inappropriate initiation in opioid-naïve individuals is a major overdose risk

Common:

• Dose-dependent respiratory depression and hypoventilation
• Sedation, dizziness, and altered mental status
• Nausea and vomiting
• Constipation with repeated dosing or infusions
• Pruritus and mild flushing

Serious:

• Apnea and severe respiratory depression: Requiring airway support and naloxone
• Chest wall rigidity and glottic rigidity: Especially with high, rapid IV doses; may require neuromuscular blockade and mechanical ventilation
• Profound bradycardia or asystole: Especially with high doses or in combination with other negative chronotropes
• Severe hypotension: Particularly in hypovolemic or hemodynamically unstable patients
• Opioid use disorder, tolerance, and withdrawal: With prolonged use
• Accidental overdose and death: Particularly with high-potency formulations (concentrated IV, transdermal, transmucosal) and in opioid-naïve patients

• Pediatrics: Use weight-based dosing (0.5–1 mcg/kg IV for acute pain); lower doses in neonates/infants; requires specialist guidance and close monitoring
• Pregnancy: Opioids cross the placenta; chronic use during pregnancy can lead to neonatal abstinence syndrome; use lowest effective dose for shortest duration when necessary
• Older Adults: Increased sensitivity to respiratory depression and sedation; start with lower doses (e.g., 25 mcg IV) and titrate slowly
• Renal Impairment: Clearance of fentanyl itself is relatively preserved, but dose reductions and slower titration recommended in severe dysfunction
• Hepatic Impairment: Reduced metabolism can increase exposure and prolong effect; use lower initial doses and slower titration with close monitoring

• Continuous pulse oximetry and frequent respiratory rate assessment: After IV/IN dosing; capnography for moderate/deep sedation, ventilated patients, or high-risk individuals
• Blood pressure and heart rate: At baseline and after dosing, especially in patients with cardiovascular disease or when co-administered with sedatives
• Pain scores, sedation scales (e.g., RASS), and agitation/delirium assessments: In ICU patients receiving continuous fentanyl infusions
• Signs of opioid toxicity: Pinpoint pupils, hypoventilation, unresponsiveness; readiness to administer naloxone when indicated
• For long-term use: Monitor for constipation, endocrine effects, tolerance and dependence, and signs of misuse or diversion

• 1. Cheng, J., & Cohen, S. P. (2024). Fentanyl. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459275/
• 2. DrugBank Online. (2024). Fentanyl (DB00813). DrugBank. https://go.drugbank.com/drugs/DB00813
• 3. Murphy, M. F., & Szokol, J. W. (2019). Opioid analgesics in anesthesia practice. In Miller's anesthesia (9th ed.). Elsevier.
• 4. Sinclair, J., & O'Connor, G. (2016). Intranasal fentanyl for the management of acute pain in children. Journal of Paediatrics and Child Health, 52(10), 924–931. https://doi.org/10.1111/jpc.13329
• 5. U.S. Food and Drug Administration. (2023). Fentanyl citrate injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov